What complementary medications can be used to assist with Suboxone (buprenorphine/naloxone) therapy and nicotine cessation?

Complementary Medications for Suboxone and Nicotine Cessation

For patients on Suboxone (buprenorphine/naloxone) who smoke, the preferred approach is combination nicotine replacement therapy (long-acting patch plus short-acting gum/lozenge/spray) OR varenicline, both paired with behavioral counseling for at least 12 weeks. 1

Nicotine Cessation Pharmacotherapy

Primary Treatment Options

Combination NRT is the safest and most recommended approach for patients on Suboxone:

• Long-acting: Nicotine patch dosed to match daily nicotine consumption (typically 21 mg, but may require 35-42 mg for heavy smokers)
• Short-acting: Nicotine gum, lozenge, inhaler, or nasal spray for breakthrough cravings
• Duration: Minimum 12 weeks, with evidence supporting extension to 6-12 months 2, 1

The combination approach is critical—inadequate NRT dosing is a frequent cause of cessation failure 1. Calculate nicotine replacement 1:1 based on cigarette consumption (1 cigarette = 1-2 mg nicotine; 1 pack/day = at least 20 mg nicotine needed) 1.

Alternative: Varenicline

Varenicline can be used but requires careful consideration in Suboxone patients:

• Standard dosing: Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Week 2-12: 1 mg twice daily 2
• Critical contraindication: Avoid in patients with brain metastases due to seizure risk 2
• Monitor closely for: Nausea (very common), neuropsychiatric symptoms (depression, suicidal ideation), though recent evidence shows these are uncommon 3
• Varenicline increases cessation rates 2-3 fold compared to unassisted attempts and shows modest superiority over NRT 3

Bupropion: Use With Extreme Caution

Bupropion is NOT recommended as first-line in Suboxone patients due to significant drug interaction concerns:

• Bupropion lowers seizure threshold (0.1% seizure risk) 4
• Absolute contraindication in patients with brain metastases or seizure history 2
• The Suboxone label warns about CNS depression with combined CNS depressants 5
• If used: 150 mg once daily for 3 days, then 150 mg twice daily for 7-12 weeks 2

Critical Safety Considerations for Suboxone Patients

Respiratory Depression Risk

The Suboxone FDA label explicitly warns about respiratory depression, particularly with concomitant CNS depressants 5. While NRT does not cause respiratory depression, be vigilant about:

• Avoiding benzodiazepines, alcohol, and other opioids during treatment
• Monitoring for signs of CNS depression if using varenicline or bupropion
• Naloxone may not reverse buprenorphine-induced respiratory depression 5

Hepatic Monitoring

Both Suboxone and smoking cessation medications are hepatically metabolized:

• Obtain baseline liver function tests before initiating Suboxone 5
• Monitor periodically during combined treatment
• Hepatic impairment increases plasma levels of both buprenorphine and naloxone 5

Medication Tolerability Issues

If patients experience adverse effects from buprenorphine-naloxone (nausea, headache, bilateral flank pain), consider switching to buprenorphine monoproduct 6. Naloxone absorption, though minimal sublingually, may cause idiosyncratic reactions in sensitive individuals 6.

Behavioral Therapy Integration

Pharmacotherapy alone is insufficient—behavioral counseling must be combined with medications:

• Minimum of 4 sessions, ideally 8+ sessions with 90-300 minutes total contact time 7
• Skills training, social support, and motivational interviewing 2
• Follow-up within 2-3 weeks of initiating therapy, then at minimum 12-week intervals 2
• Nicotine withdrawal peaks at 1-2 weeks; encourage adherence through brief slips 2

Treatment Algorithm

1. Assess nicotine dependence: Calculate daily cigarette consumption to determine NRT dosing
2. First-line: Combination NRT (patch + short-acting form) for 12 weeks minimum
3. If NRT fails or patient prefers alternative: Varenicline (after screening for contraindications)
4. Monitor closely: Week 2-3 follow-up, then every 12 weeks
5. If persistent smoking: Increase NRT dose, switch to varenicline, or consider combination varenicline + NRT (emerging evidence) 8
6. Avoid: Bupropion as first-line due to seizure risk and CNS depression concerns with Suboxone

Common Pitfalls

• Underdosing NRT: Most common cause of failure—match nicotine consumption 1:1 1
• Stopping treatment too early: 12 weeks is minimum; many patients benefit from 6-12 months 1
• Neglecting behavioral therapy: Doubles success rates when combined with pharmacotherapy 7
• Using buprenorphine-naloxone when monoproduct would be better tolerated: Consider switching if adverse effects occur 6